Use of a chimeric adenovirus vector enhances XXXX production and bone formation.

@entity1 @entity1841 @entity85 @entity11650
Recombinant adenoviral vectors have potential for the treatment of a variety of @entity85 and such gene therapy systems have been a recent research focus in orthopedic surgery. In studies reported here, two different adenovirus vectors have been compared for their ability to transduce @entity1 bone marrow mesenchymal stem cells (hBM-MSCs) and elicit bone formation in vivo. Vectors consisted either of standard @entity11650 ( @entity11650 ) vector or a chimeric @entity11650 vector that contains an adenovirus type 35 fiber (Ad5F35), which has been recently demonstrated to bestow a different cellular tropism, and a complete cDNA encoding @entity1 @entity1841 ( @entity1841 ). Studies were also conducted to compare the transduction efficiency of these vectors using enhanced green fluorescent protein (GFP). hBM-MSCs transduced with Ad5F35 vectors had higher levels of transgene expression than those transduced with @entity11650 vectors. The results also demonstrate that hBM-MSCs lack the coxsackie-adenovirus receptor (CAR), which is responsible for cellular adsorption of @entity11650 . Therefore, the data suggest that @entity11650 virus adsorption to hBM-MSCs is inefficient. Ad5 @entity1841 - or Ad5F35BMP2-transduced hBM-MSCs were also compared in an in vivo heterotopic bone formation assay. Mineralized bone was radiologically identified only in muscle that received the Ad5F35BMP2 transduced hBM-MSCs. In summary, Ad5F35BMP2 can efficiently transduce hBM-MSCs leading to enhanced bone formation in vivo.
